CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry


Por: de la Torre, EP, Serrano, J, Barragán, E, Ayala, R, Calasanz, MJ, Chillón, MC, Soria, E, Bilbao-Sieyro, C, Cabello, A, Lavilla-Rubira, E, Gallego, AA, Gómez, JL, Simón, JAP, Rodríguez-Veiga, R, Martínez-Cuadrón, D, Vives, S, Burgues, JMB, Alis, FI, Gil, C, Algarra, LA, Castaño, T, Tormo, M, del Castillo, TB, Sánchez, MDM, Casado, M, Fernández, OA, Herrera-Puente, P, Vicente, MBV, Colorado, M, Toscano, MDM, González, BJ, Ruiz, MP, Rubio, MO, Sánchez-García, J and Montesinos, P

Publicada: 8 ene 2026
Resumen:
The aim of our study was to analyze the incidence, co-mutation pattern, and prognostic impact of CEBPA gene mutations in a large multicenter consecutive series of 1367 adult patients AML patients treated with non-IT modalities. A total of 83 patients (6.1%) had mutations in CEBPA gene. Among these, 34 (2.5%) harbored mutations located in bZIP domain (bZIP in-frame N = 6) and 49 (3.6%) in other regions of the gene (other CEBPAmut). Genes most frequently co-mutated in these CEBPAmut patients were TET2 (45.8%, N = 38), SRSF2 (42.2%, N = 35), and ASXL1 (40.9%, N = 34). Using the Bradley-Terry model we identified that mutations in MDS-related genes, in TP53, and in epigenetic regulators appear to occur earlier. In contrast, genes involved in activating cell signaling appeared to occur later than CEBPAmut. Overall Survival (OS) of non-IT AML patients was analyzed according to the type of CEBPAmut. Median OS was 11.6 months in CEBPA-bZIP patients compared to 9.0 and 6.9 for patients with other CEBPAmut or CEBPAwt, respectively. When selecting 1129 AML patients treated with HMA or HMA-based combinations, CEBPA-bZIP patients had a median survival time of 11.6 months (range 9.6-NR) and 2.5 years survival probability of 20.1% which were outcomes comparable to remaining ELN2024 favorable patients. We concluded that our series of non-IT AML patients within the PETHEMA registry confirm a low percentage of CEBPA mutated cases which are frequently co-mutated with MDS related genes. Those CEBPA-bZIP cases harbor a similar median OS than those belonging to favorable ELN2024 risk category.

Filiaciones:
de la Torre, EP:
 Univ Cordoba UCO, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIBIC, Hematol Unit, Cordoba, Spain

Serrano, J:
 Univ Cordoba UCO, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIBIC, Hematol Unit, Cordoba, Spain

Barragán, E:
 Hlth Res Inst La Fe IIS La Fe, Biomed Res Networking Ctr Oncol CIBERONC, Valencia, Spain

 La Fe Univ, Clin Anal Serv, Accredited Hematol Res Grp, Valencia, Spain

 Polytech Hosp, Hlth Res Inst La Fe IIS La Fe, Valencia, Spain

Ayala, R:
 Univ Complutense Madrid, 12 Octubre Univ Hosp, Spanish Natl Canc Res Ctr CNIO, Dept Med, Madrid, Spain

Calasanz, MJ:
 Univ Navarra, Navarra Inst Hlth Res IdiSNA, Hematol Dis Lab, CIMA LAB Diagnost, Pamplona, Spain

Chillón, MC:
 Salamanca Univ Hosp HUS IBSAL, Canc Res Ctr IBMCC USAL CSIC, Hematol Dept, CIBERONC, Salamanca, Spain

Soria, E:
 Univ Seville, Virgen del Rocio Univ Hosp, Inst Biomed Seville IBIS, CSIC, Seville, Spain

Cabello, A:
 Nuestra Senora de Candelaria Univ Hosp, Santa Cruz De Tenerife, Spain

Gallego, AA:
 Leon Univ Hosp, Leon, Spain

Gómez, JL:
 Burgos Univ Hosp, Burgos, Spain

Simón, JAP:
 Univ Seville, Virgen del Rocio Univ Hosp, Inst Biomed Seville IBIS, CSIC, Seville, Spain

Rodríguez-Veiga, R:
 Polytech Hosp, Hlth Res Inst La Fe IIS La Fe, Valencia, Spain

 La Fe Univ, Hematol Dept, Accredited Hematol Res Grp, Valencia, Spain

Martínez-Cuadrón, D:
 Polytech Hosp, Hlth Res Inst La Fe IIS La Fe, Valencia, Spain

 La Fe Univ, Hematol Dept, Accredited Hematol Res Grp, Valencia, Spain

:
 Hosp Germans Trias i Pujol, Josep Carreras Leukaemia Res Inst, ICO, Badalona, Spain

Burgues, JMB:
 San Pedro de Alcantara Hosp, Caceres, Spain

Alis, FI:
 Valencia Gen Hosp, Valencia, Spain

Gil, C:
 Alicante Gen Hosp, Alicante, Spain

Algarra, LA:
 Albacete Gen Hosp, Albacete, Spain

Castaño, T:
 Fdn Jimenez Diaz Univ Hosp, Madrid, Spain

Tormo, M:
 Univ Valencia, Univ Clin Hosp, INCLIVA Hlth Res Inst, Valencia, Spain

Sánchez, MDM:
 Univ Complutense Madrid, 12 Octubre Univ Hosp, Spanish Natl Canc Res Ctr CNIO, Dept Med, Madrid, Spain

Casado, M:
 Infanta Cristina Univ Hosp Badajoz, Badajoz, Spain

Fernández, OA:
 Basurto Univ Hosp, Bilbao, Spain

Vicente, MBV:
 Salamanca Univ Hosp, Salamanca, Spain

Colorado, M:
 Marques de Valdecilla Univ Hosp, Santander, Spain

Toscano, MDM:
 Virgen Macarena Univ Hosp, Seville, Spain

González, BJ:
 Univ Hosp Canary Isl, Santa Cruz De Tenerife, Spain

Ruiz, MP:
 Doctor Peset Univ Hosp, Valencia, Spain

Rubio, MO:
 Lozano Blesa Univ Clin Hosp, Zaragoza, Spain

Sánchez-García, J:
 Univ Cordoba UCO, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIBIC, Hematol Unit, Cordoba, Spain

Montesinos, P:
 Hlth Res Inst La Fe IIS La Fe, Biomed Res Networking Ctr Oncol CIBERONC, Valencia, Spain

 Polytech Hosp, Hlth Res Inst La Fe IIS La Fe, Valencia, Spain

 La Fe Univ, Hematol Dept, Accredited Hematol Res Grp, Valencia, Spain

Univ Las Palmas Gran Canaria, Dr Negrin Univ Hosp Gran Canaria, Las Palmas Gran Canaria, Spain
Lucus Augusti Univ Hosp, Lugo, Spain
Cent Univ Hosp Asturias, Univ Inst Oncol IUOPA, Inst Hlth Res Principal Asturias ISPA, Oviedo, Spain
Puerta de Hierro Majadahonda Univ Hosp, Madrid, Spain
ISSN: 10991069





Hematological Oncology
Editorial
John Wiley & Sons Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 44 Número: 1
Páginas:
WOS Id: 001656811700001
ID de PubMed: 41508698

MÉTRICAS